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Abstract  
Objective: This study was performed to prospectively and independently validate 
the global antiphospholipid syndrome score (GAPSS), a system derived from the 
combination of independent risk factors for thrombosis, including antiphospholipid 
antibodies (aPL) and conventional cardiovascular risk factors.  
Methods: The GAPSS was applied to 51 consecutive SLE patients, all positive for 
aPL and prospectively followed up for 32.94±12.06 months. Of them, 48 were 
female with a mean age of 37.35±12.15 at entry. The GAPSS was calculated 
yearly for each patient by adding together the points corresponding to the risk 
factors.  
Results: An increase in the GAPSS (entry vs. last visit) was seen in patients who 
experienced vascular events (n=4, 7.5±4.36 vs. 10.0±5.4, p=0.032). No changes 
were observed in those without thrombosis (n=47, 8.28±4.88 vs. 7.13±5.75, p= 
0.24).  
An increase in the GAPSS during the follow up was associated with a higher risk 
of vascular events (RR 12.30 [95%CI 1.43-106.13, p=0.004), and an increase of 
more than 3 points showed the best risk accuracy for vascular events (HR 48 
[95%CI 6.90-333.85, p=0.0001).  The cumulative proportion of thrombosis-free 
individuals was lower in patients whose GAPSS was increased by 3 or more 
points (p=0.0027). 
Conclusion: We have prospectively demonstrated that GAPSS is a valid tool for 
accurate prediction of vascular events in SLE patients with aPL.   
4 
 
Significance and Innovation  
-Global APS Score (GAPSS) is derived from the combination of independent risk 
factors for thrombosis and pregnancy loss, taking into account the antiphospholipid 
antibodies (aPL) profile (criteria and non-criteria aPL), the conventional 
cardiovascular risk factors, and the autoimmune antibodies profile 
-We have prospectively demonstrated that GAPSS is a valid tool for accurate 
prediction of vascular events in SLE patients with aPL. 
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Introduction 
The antiphospholipid syndrome (APS) is a thrombophilic autoimmune disorder 
characterised by thrombosis (arterial and/or venous) and/or pregnancy loss, 
associated with the presence of a specific group of autoantibodies, the so-called 
antiphospholipid antibodies (aPL). aPL have been demonstrated to be closely 
associated with thrombotic manifestations,(1) albeit the available studies differ from 
design, patients selection criteria, aPL profile and associated risk factors.  
Whether there are specific serologic or clinical findings that can predict which 
patients with aPL are most likely to experience a thrombotic event, this is still 
controversial. While some studies have suggested different antibody profiles, such as 
simultaneous presence of LAC, aCL, and anti-β2GPI,(2) or LAC, anti-β2GPI and 
aPS/PT,(3) as identifiers of at-risk status others suggest that clinical characteristics 
such as hypertension (4) are predictive of risk.  
Recently, we conducted a cross-sectional study in a large cohort of well-
characterised Systemic Lupus Erythematosus (SLE) patients applying a newly 
developed risk score for APS (Global APS Score or GAPSS).(5) This score was 
derived from the combination of independent risk factors for thrombosis and 
pregnancy loss, taking into account the aPL profile (criteria and non-criteria aPL), the 
conventional cardiovascular risk factors, and the autoimmune antibodies profile.(5)  
As a result, we demonstrated that a risk profile could be successfully assessed, 
suggesting that GAPSS is a potential quantitative predictor of APS-related clinical 
manifestations risk in SLE. 
In the present study, we aimed at prospectively evaluate the clinical relevance of 
GAPSS in a cohort of SLE patients with aPL but without previous thrombotic events.   
6 
 
Patients and Methods 
 
Patients 
This study included 51 consecutive SLE patients. Of them, 48 were female with a 
mean age 37.35±12.15. All patients attended the Louise Coote Lupus Unit at St 
Thomas Hospital, London as part of a large, randomized, double blind clinical trial 
evaluating the efficacy and safety of low dose aspirin (LDA) versus LDA plus low-
intensity warfarin in the primary thrombosis prevention in aPL positive patients with SLE 
(ALIWAPAS).(6) 
Inclusion criteria were: a) the presence of aPL (medium or high titers of aCL defined 
as IgG>20 GPL and/or IgM >20 MPL and/or LA positive) on at least two occasions, 
with an interval of 6 weeks, during the year previous to the inclusion into the study, b) 
SLE patients meeting 4 or more ACR criteria for the classification of SLE (7) and c) 
Age between 18-65 years. Exclusion criteria were: positivity for aPL but without SLE, 
previous thrombotic events, uncontrolled hypertension, active gastric or duodenal 
ulcer, severe thrombocytopenia (platelets <50.000mm3), hepatic failure, severe 
illness i.e. cancer, allergy to aspirin, allergy to warfarin, or being currently pregnant.  
The mean follow-up was 32.94±12.06 months. Demographic, clinical and laboratory 
characteristics are summarised in Table 1.  
By the original study design (6), patients had an initial visit to obtain the necessary 
data for randomization. After being allocated to one of the treatment groups, they had 
a baseline assessment, followed by six monthly visits. Data regarding conventional 
risk factors for thrombosis were collected at all visits. All clinical events (notably 
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thrombotic or hemorrhagic events) were particularly scrutinized with standard 
methods to objectively document them. 
Ethical approval was obtained from the Guy’s and St Thomas’ Ethics committee and 
all patients involved in this study gave their written consent.  
 
Assessment of Cardiovascular Risk Factors 
Cardiovascular risk factors were assessed following NICE guidelines (8, 9) In detail, 
enrolled patients underwent at each visit a physical examination, blood pressure 
determination, and phlebotomy for vascular risk factors according to ALIWAPAS 
protocol. Arterial hypertension was defined as appropriately sized cut off high blood 
pressure (140/90 mmHg or higher), at least in two occasions or use of oral anti-
hypertensive medications (8). Serum total and HDL cholesterol levels were 
determined with standardized enzymatic methods and interpreted according to 
current cut off values (10) (total cholesterol of < 5.0 mmol/l, for LDL cholesterol of < 
3.0 mmol/l).   
Autoantibodies detection 
aPL profile included anticardiolipin antibodies (aCL), lupus anticoagulant (LA), anti-
β2glycoprotein-I antibody (anti-β2GPI), and  antibodies to 
phosphatidylserine/prothrombin complex (aPS/PT).  
The aCL and anti-β2GPI were detected by ELISA as described previously.(11, 12) 
Plasma samples were tested for the presence of LA according to the recommended 
criteria from the ISTH Subcommittee on Lupus Anticoagulant-Phospholipid-
dependent antibodies.(13, 14) 
8 
 
The aPS/PT were detected as previously reported. (15, 16)  Antinuclear antibodies 
were measured by indirect immunofluorescence on rodent liver cells, and anti-dsDNA 
antibodies by radioimmunoassay (Farr assay).  
GAPSS calculation 
The GAPSS system was calculated for each patient as previously reported, by 
adding together the points corresponding to the risk factors at each visit.(5, 6) 
GAPSS was computed on a yearly basis and at the time of the event in patients who 
developed thrombosis. Assigned points to risk factors based on the linear 
transformation of the corresponding β regression coefficient were, as previously 
reported, 3 for hyperlipidemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for 
anti-β2GPI IgG/IgM, 3 for aPS/PT IgG/IgM and 4 for LA.(5) (Table 2) 
Outcome measures 
The primary outcome measure for the main trial was thrombosis. As only objectively 
verified thrombotic events were considered as an end point, accurate investigations 
were performed in order to document the event, as described in the original 
publication.(6)  
Statistical Analysis 
Categorical variables are presented as numbers and percentages, and continuous 
variables are presented as means ±SD. The significance of baseline differences was 
determined by the chi-square test, Fisher's exact test, or the unpaired t-test, as 
appropriate. A two-sided P value of less than 0.05 was considered to indicate 
statistical significance. Sensitivity and specificity for different cut off values were also 
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assessed for recurrences.  The discriminative ability (ability of the score to classify 
patients and overall predictive performance for different cut off) of the GAPSS was 
calculated by measuring the area under the receiver operating characteristic (ROC) 
curve. The cumulative risk for experiencing the event was estimated by means of the 
Kaplan–Meier method. The results were presented as hazard ratios with their 95% 
confidence intervals (HR [95%CI]) and p values. Proportional-hazards regression 
analysis with the Wald significance test was then used to examine the change in 
GAPSS and patients characteristics on the risk of developing thrombosis.  
All statistical analyses were performed using SPSS 19.0 (Chicago, Illinois, USA). 
Results 
Overall, baseline GAPSS was 8.21±4.08 [range 3-17].  
The primary end point occurred in 4/51 patients from this cohort (7.8%). The 
incidence of thrombotic events was 2.68 events/100 person-years.  
An increase in the GAPSS (entry vs. last visit) was seen in patients who experienced 
vascular events (n=4, 7.5±4.36 vs. 10.0±5.4, p=0.032). No changes were observed in 
those without thrombosis (n=47, 8.28±4.88 vs. 7.13±5.75, p= 0.24) (Figure 1.A). 
When GAPSS values were analysed yearly, an increase was also observed only in 
patients who developed vascular events when compared to those without (p= 
0.0316) (Figure 1.B). 
Demographic and clinical characteristics of patients who developed vascular events 
are summarised in Table 3. 
An increase in the GAPSS during the follow up was associated with a higher risk of 
vascular events (RR 12.30 [95%CI 1.43-106.13, p=0.004). A separate analysis 
applying an adjusted version of the score which excluded aPS/PT (adjusted GAPSS 
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or aGAPSS) was performed. In this adjusted form, an increase in the aGAPSS during 
the follow up was also associated with a higher risk of vascular events (RR 8.60 
[95%CI 1.64-88.90, p=0.015). 
An increase of more than 3 GAPSS points seemed to have the best risk accuracy for 
vascular events (HR 48 [95%CI 6.90-333.85, p=0.0001).  Consistently, a decrease in 
the GAPSS was observed in 22 patients: in 8 due to successful treatment of 
hyperlipidemia and/or arterial hypertension, in 14 due to changes in their aPL profile. 
None of these patients developed any vascular event.   
No changes in SLEDAI (entry vs. last visit) were seen in patients who experienced 
vascular events (n=4, 1±2 vs. 1.5±3, p=0.79) when compared to those without 
thrombosis (n=47, 1.6±4.75 vs. 1.9±4.23, p= 0.88). 
The risk of thrombosis was also evaluated by Kaplan-Meier analysis. The cumulative 
proportion of thrombosis-free individuals was lower in patients whose GAPSS was 
increased by 3 or more points (p=0.0027) (Figure 1.C).  
 
Discussion 
This study was aimed at prospectively evaluating the clinical relevance of GAPSS in 
predicting the risk of thrombotic event in a cohort of 51 SLE patients from a single 
center, prospectively followed up as part of  a larger RTC.(6)  
In this study, we showed that an increase in the GAPSS during the follow up is seen 
in those SLE patients who experienced vascular events when compared to those 
who did not experience such an event. Recent studies have suggested that different 
aPL profiles are able to identify patients at a higher risk of thrombosis. Patients with 
“triple postivity”  for aCL, anti-β2GPI and LA,(2) and those with anti-2GPI, aPS/PT 
and LA,(3) have been shown to be at a higher risk of developing thromboembolic 
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events. Moreover, conventional cardiovascular risk factors have been proved to 
strongly contribute to the development of thrombosis in APS. An early prospective 
study of 404 subjects, 226 with APS and 178 asymptomatic carriers of aPL, found 
that 50% of patients with APS had coincident risk factors for arterial thrombosis, such 
as hypercholesterolemia and arterial hypertension, at the time of the first thrombotic 
event.(17)  A recent prospective study in 258 aPL carriers showed that hypertension 
and LA were significantly predictive of the first thrombotic event.(4) Moreover, 
hypertension and LA were identified by multivariate logistic regression analysis as 
independent risk factors for thrombosis in this cohort (4) and others.(5) 
Our data indicate that the combination of certain aPL tests along with conventional 
cardiovascular risk factors should be considered when assessing the risk of 
thrombosis. A profile including hyperlipidemia, arterial hypertension, aCL anti-β2GPI, 
aPS/PT and LA form the bases for the GAPSS. In our study, patients who 
experienced an increase in GAPSS of more or equal than 3 during the follow-up had 
a 48-times increased risk to develop a thrombotic event.  
In this setting, the GAPSS represents an important tool allowing for a substantial 
improvement in quantifying the risk to develop thrombosis.   
We accept that this approach has some limitations. Firstly, patients were randomized 
for LDA vs. LDA+ low-intensity warfarin  in the original study, a trial on primary 
thromboprophylaxis designed back in 1998.(6)  In the main ALIWAPAS trial, LDA+ 
low-intensity warfarin  did not result in a significant reduction in thrombotic event rate. 
When adjusted for the treatment regimen, we also observed no differences in 
thrombotic incidence in patients treated with in LDA vs LDA+ low-intensity warfarin in 
this subgroup.We acknowledge that this therapeutic approach is not currently 
adopted in the clinical practice anymore; however, as the original trial failed in 
12 
 
observing a significant difference in thrombotic event rate in the two arms, we feel 
that this did not significantly impact on the validation of GAPSS in this study.  In 
addition, the ALIWAPAS trial recruitment was based on the Sapporo criteria (18). 
However, no anti-β2GPI antibodies alone are seen our experience, therefore this 
should not limit our data (3).  
Second, the effect of targeted therapy for hypertension and/or hyperlipidemia, both 
significant variables when evaluating risk, could not be assessed, as treatment varied 
according to the clinical manifestations and clinician judgement. However, no patient 
who experienced a decrease in the GAPSS value (8 out of 51 patients) due to a 
better control of co-morbilites experienced a thrombotic event, supporting the 
concept that an effective control of conventional risk factors could reduce the risk of 
developing future events.    
Third, cases of aPL levels fluctuation and conversion from positive to negative have 
been reported.  Changes in the score may be due to aPL profile change and  to a 
better/worse control of other risk factors (19, 20). Indeed, aPL titers fluctuation can 
be observed in the routine clinical practise and its clinical significance is still under 
debate.  
Fourth, disease activity has been shown as an important determinant in the 
occurrence of thrombotic events in SLE patients (21). However, in this study, no 
changes in SLEDAI (entry vs. last visit) were seen in patients who experienced 
vascular events when compared to those without thrombosis. Moreover, also when 
adjusted for the immunosuppressive regimen, we observed no differences in 
thrombotic incidence in patients with or without immunosuppressant agents.  
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Finally, we reported two events as transient ischemic attacks, defined according to 
National Institute of Neurological Disorders and Stroke.(22) In both the cases 
hyperintensity lesions compatible with small vessels ischemia were found at MRI.   
In summary, in this study we validated the GAPSS in a prospective cohort as a valid 
tool for risk stratification for thrombosis. Such an approach on the categorization of 
APS patients based upon a quantitative score may, in the future, influence the clinical 
judgment and therapeutic approach.  
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LEGEND 
 
Figure 1. 
A. Distribution of GAPSS (entry vs. last visit) according to clinical manifestations. 
Data are shown as box plots, where each box represents the 25 th to 75th 
percentiles: lines inside the box represent the median. The whiskers represent 
the 95%CI.  Higher values of GAPSS were seen in patients who developed 
vascular events (VE+ve) when compared to those without (VE-ve). 
 
B. Distribution of GAPSS analysed yearly according to clinical manifestations. 
Data are shown as box plots, where each box represents the 25 th to 75th 
percentiles: lines inside the box represent the median. The whiskers represent 
the 95%CI.  Higher values of GAPSS were seen in patients who developed 
vascular events (VE+ve) when compared to those without (VE-ve). 
 
C.  Kaplan-Meier analysis of the risk of vascular event. The cumulative proportion 
of thrombosis-free individuals was lower in patients whose GAPSS was 
increased by 3 or more points (Delta ≥ 3).  
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